abstract: Very little research evidence is available regarding current safety and security procedures on acute @entity146 wards. This includes controversial areas such as the temporary removal of personal property, the searching of @entity1 and visitors, the use of alarms and modern technology, and locking of entrances to regulate those entering and leaving. This is also despite widening dismay over increasing violence within a variety of hospital settings, the comparatively high risk of physical assault faced by mental health professionals and an abundance of literature and training in regards to violence management and prevention. To gain an understanding of current safety and security measures, a London-wide survey of acute admission wards was undertaken revealing a wide variety of measures and policies in operation. Over 100 @entity9462 and private wards were sent questionnaires; there was a response rate of 70%. Results show that a significant proportion of acute admission wards are now locked at all times and a small proportion of units have 24-hour security/reception staff on-site and a low level of modern technology usage such as CCTV and electronic access systems. There is wide variation in items banned, restrictions placed on inpatients, and the searching of @entity1 and visitors. Two independently varying emphases of ward security policies were identifiable, the first aimed at preventing harm to @entity1 using door security, banning of item and restrictions on inpatients. The other is aimed at reducing risks to staff via searching of @entity1 , use of security guards and sophisticated alarm systems. There is some preliminary evidence that these security policies are differentially associated with levels of absconding and violent incidents. Further research to guide practice is urgently required.

title: Safety and security policies on XXXX acute admission wards: results from a London-wide survey.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric']

answer: @entity146 :: (MESH:D001523,Disease) :: ['psychiatric']


abstract: The purpose of this study was to test whether screening at @entity935 receptors performed with a recently described functional assay for G-protein coupled receptors (GPCRs) provides data that correlate significantly with radioligand binding data in the literature, thus possibly allowing researchers to replace radioligand binding with nonradioactive functional screening. @entity1 @entity935 receptors @entity12840 and hD2L (representing Gs [ @entity12840 ] or Gi [hD2L] coupled GPCRs) were recombinantly expressed in @entity1 embryonic kidney (HEK293) cells. Cells were loaded with Oregon Green 488 BAPTA-1/AM and evenly distributed in 384 well plates. Seventeen test compounds were screened for agonistic activity by injection into the cell suspension and monitoringH of intracellular @entity141 with a fluorescence microplate reader. Then, standard agonists (100nM @entity2344 for @entity12840 , 30nM @entity11640 for hD2L) were injected into wells preincubated with test compounds (screening for antagonism). Injection of various agonists resulted in a concentration-dependent increase in fluorescence. Further, preincubation of antagonists with @entity935 receptor expressing cells inhibits concentration-dependent the agonist-induced increase in fluorescence. Calculated apparent functional Ki values correlate with radioligand binding data in the literature (r2 = 0.7796 for @entity12840 , r2 = 0.7743 for D2). The correlation between apparent functional Ki values and radioligand binding data for the 17 tested compounds suggests that screening of test compounds at @entity935 receptors with the functional @entity141 assay can replace radioligand binding studies. Furthermore, besides apparent Ki values, information about agonistic or antagonistic properties of a test compound can be obtained with the functional @entity141 assay.

title: Quantitative comparison of functional screening by measuring intracellular @entity141 with radioligand binding at recombinant @entity1 XXXX receptors.

entities_list: @entity11640 :: ('MESH:D019257', 'Chemical') :: ['quinpirole']

entities_list: @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine']

answer: @entity935 :: (MESH:D004298,Chemical) :: ['dopamine']


abstract: BACKGROUND: @entity488 ( @entity14492 ) therapeutic response and @entity137 are associated with high inter-individual variability attributed to variation in its pharmacokinetics. Plasma concentrations below 1   g/ml may result in virologic failure and above 4   g/ml, may result in central nervous system adverse effects. This study used population pharmacokinetics modeling to explore the influence of demographic and pharmacogenetic factors including @entity488 - @entity1215 interaction on @entity14492 pharmacokinetics, towards safer dosing of @entity14492 . METHODS: @entity1 receiving an @entity14492 -based regimen for their antiretroviral therapy and a @entity1215 -containing anti- @entity1906 regimen were recruited. @entity14492 plasma concentrations were measured by HPLC and genomic DNA genotyped for variants in the @entity11670 , @entity5944 and @entity1262 genes. All @entity1 were evaluated for central nervous system adverse effects characterised as @entity25 , @entity1833 and headaches using the WHO ADR grading system. A pharmacokinetic model was built in a forward and reverse procedure using nonlinear mixed effect modeling in NONMEM VI followed by model-based simulations for optimal doses. RESULTS: @entity11670 *6 and *18 variant alleles, weight and sex were the most significant covariates explaining 55% of inter-individual variability in @entity14492 clearance. @entity1 with the @entity11670 *6TT genotype had a 63% decrease in @entity14492 clearance despite their @entity11670 *18 genotypes with females having 22% higher clearance compared to males. There was a 21% increase in clearance for every 10  kg increase in weight. The effect of @entity1906 / @entity645 co-treatment versus @entity645 treatment only was not statistically significant. No clinically relevant association between @entity11670 genotypes and CNS adverse effects was seen, but @entity1 with CNS adverse effects had a 27% lower clearance compared to those without. Model- based simulations indicated that all carriers of @entity11670 *6 TT genotype would be recommended a dose reduction to 200  mg/day, while the majority of extensive metabolisers may be given 400  mg/day and still maintain therapeutic levels. CONCLUSION: This study showed that screening for @entity11670 functional variants has a high predictability for @entity488 plasma levels and could be used in prescribing optimal and safe @entity14492 doses.

title: @entity11670 *6, @entity11670 *18, Body weight and sex are predictors of @entity488 pharmacokinetics and treatment response: population pharmacokinetic modeling in an XXXX /AIDS and @entity1906 cohort in Zimbabwe.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity488 :: ('MESH:C098320', 'Chemical') :: ['efavirenz', 'Efavirenz']

entities_list: @entity1833 :: ('MESH:D006212', 'Disease') :: ['hallucinations']

entities_list: @entity1215 :: ('MESH:D012293', 'Chemical') :: ['rifampicin']

entities_list: @entity25 :: ('MESH:D012893', 'Disease') :: ['sleep disorders']

answer: @entity645 :: (57667,Species) :: ['HIV']


abstract: Recent advances on the pathogenesis of chronic @entity110 have defined a group of @entity1 with autoantibodies directed to the IgE or to the alpha chain of the Fc high affinity receptor of IgE, @entity220 . These antibodies are detected in vivo through the autologous serum test (AST) and in vitro with a variety of techniques. We here describe 37 @entity1 with chronic @entity110 , 28 female and 9 male, with a f/m ratio of 3.1. Mean age at onset was 36.5 years (range 16-78). AST was positive in 25 (68%) of 37 patients. Serum induced a wheal significantly larger than plasma (122 +/- 78 mm2 vs 57 +/- 66 mm2, p < 0.05). Median persistence of the chronic @entity110 , estimated by Kaplan-Meyer analysis, was 437 days, with no difference between AST(+) and AST(-) @entity1 (437 vs. 369, p = 0.18). Mean IgE concentration was 157 +/- 173 IU/mL, as expected in an unselected population. Basophil count was lower in @entity1 compared with controls (17 +/- 12 cel/microL vs. 43 +/- 27 cel/microL, p < 0.008). Only sera from 2/7 (28.6%) @entity1 AST (+) and very low basophil count consistently induced expression of @entity5775 . This effect was abrogated in non-releasing basophils, confirming the presence of antibodies directed to the @entity220 -IgE. We conclude that functional antibodies are present in only a minority of @entity1 and that their identification does not predict the outcome.

title: [Chronic XXXX . Clinical evolution, autologous serum test, count and activation of basophils].

entities_list: @entity110 :: ('MESH:D014581', 'Disease') :: ['urticaria']

entities_list: @entity220 :: ('2205', 'Gene') :: ['Fc epsilon RI alpha']

answer: @entity110 :: (MESH:D014581,Disease) :: ['urticaria']


abstract: Importance: The @entity1 -centered medical home (PCMH) model of primary care is being implemented in a wide variety of socioeconomic contexts, yet there has been little research on whether its effects differ by context. Clinical preventive service use, including @entity5 screening, is an important outcome to assess the effectiveness of the PCMH within and across socioeconomic contexts. Objective: To determine whether the relationship between the PCMH and @entity5 screening is conditional on the socioeconomic context in which a primary care physician practice operates. Design, Setting, and @entity1 : A longitudinal study spanning July 1, 2009, through June 30, 2012, using data from the Blue Cross Blue Shield of Michigan Physician Group Incentive Program was conducted. Michigan nonpediatric primary care physician practices that participated in the Physician Group Incentive Program (5452 practice-years) were included. Sample size and outlier exclusion criteria were applied to each outcome. We examined the interaction between practices' PCMH implementation scores and their socioeconomic context. The implementation of a PCMH was self-reported by the practice's affiliated physician organizations and was measured as a continuous score ranging from 0 to 1. Socioeconomic context was calculated using a market-based approach based on zip code characteristics of the practice's @entity1 and by combining multiple measures using principal components analysis. Main Outcomes and Measures: Breast, cervical, and @entity14 screening rates for practices' Blue Cross Blue Shield of Michigan @entity1 . Results: The implementation of a PCMH was associated with higher breast, cervical, and @entity14 screening rates across most market socioeconomic contexts. In multivariable models, the PCMH was associated with a higher rate of screening for @entity0 (5.4%; 95% CI, 1.5% to 9.3%), @entity5 (4.2%; 95% CI, 1.4% to 6.9%), and @entity14 (7.0%; 95% CI, 3.6% to 10.5%) in the lowest socioeconomic group but nonsignificant differences in screening for @entity0 (2.6%; 95% CI, -0.1% to 5.3%) and @entity5 (-0.5%; 95% CI, -2.7% to 1.7%) and a higher rate of @entity14 (4.5%; 95% CI, 1.8% to 7.3%) screening in the highest socioeconomic group. Because PCMH implementation was associated with larger increases in screening in lower socioeconomic practice settings, models suggest reduced disparities in screening rates across these contexts. For example, the model-predicted disparity in @entity0 screening rates between the highest and lowest socioeconomic contexts was 6% (77.9% vs 72.2%) among practices with no PCMH implementation and 3% (80.3% vs. 77.0%) among practices with full PCMH implementation. Conclusions and Relevance: In our study, the PCMH model was associated with improved @entity5 screening rates across contexts but may be especially relevant for practices in lower socioeconomic areas.

title: XXXX -Centered Medical Home Implementation and Use of Preventive Services: The Role of Practice Socioeconomic Context.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Participants']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'cervical cancer']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

answer: @entity1 :: (9606,Species) :: ['Patient']


abstract: @entity16546 is characterised by @entity1032 , @entity851 and a particular dysmorphology. The syndrome is rare, with a frequency of approximately one affected individual in 100,000 newborns. Mutations in two genes - @entity16221 and @entity3493 - have been identified to cause the syndrome. These two genes show strong homology and encode histone acetyltransferases (HATs), which are transcriptional co-activators involved in many signalling pathways. Loss of HAT activity is sufficient to account for the phenomena seen in @entity16546 @entity1 . Although some mutations found in @entity16221 are translocations, inversions and large deletions, most are point mutations or small deletions and insertions. Mutations in @entity3493 are comparatively rare. Extensive screening of @entity1 has revealed mutations in @entity16221 and @entity3493 in around 50% of cases. The cause of the syndrome in the remaining @entity1 remains to be identified, but other genes could also be involved. Here, we describe the clinical presentation of @entity16546 , review the mutation spectrum and discuss the current understanding of causative molecular mechanisms.

title: XXXX : clinical and molecular overview.

entities_list: @entity1032 :: ('MESH:D008607', 'Disease') :: ['mental retardation']

entities_list: @entity851 :: ('MESH:D006130', 'Disease') :: ['growth retardation']

entities_list: @entity16546 :: ('MESH:D012415', 'Disease') :: ['Rubinstein-Taybi', 'Rubinstein-Taybi syndrome']

answer: @entity16546 :: (MESH:D012415,Disease) :: ['Rubinstein-Taybi syndrome']


abstract: BACKGROUND: The cryopreservation of HPCs in @entity3733 has been practiced by cord blood (CB) banks worldwide. Inevitably, some detriment to biologic function occurs as the result of freezing injuries and @entity3733 @entity137 . @entity7970 , a disaccharide, is a natural cryoprotectant in organisms capable of surviving extreme dehydration and cold. The objective of this study was to establish the cryopreservation of CB under preclinical conditions using @entity7970 as a supplement to @entity3733 . STUDY DESIGN AND METHODS: In a preclinical protocol, the effects of 5-percent @entity7970 with 10-percent @entity3733 or 5-percent @entity3733 on the cryopreservation of CB MNCs or nucleated cells (NCs) were further evaluated. The read-out system consisted of a panel of HPCs: early progenitors (CFU-GEMM, long-term culture-initiating cells [LTC-IC]) and committed progenitors (CFU-GM, CFU/BFU-E, CFU-megakaryocyte [CFU-MK]). The homing and engraftment capacity of these cells were assessed in nonobese @entity6 (NOD)- @entity915 @entity19 . RESULTS: @entity7970 increased the recoveries of CFU-GM, CFU/BFU-E, CFU-GEMM, and LTC-IC by over 7.25 percent (mean), 11.9 percent, 19.2 percent, and 12.9 percent, respectively, when compared with those in paired CB samples cryopreserved in 10-percent @entity3733 . Freezing and thawing reduced the yields of CFU-MK by 35.5 percent (mean) and 28.4 percent in MNC and NC samples, respectively, and the inclusion of 5-percent @entity7970 significantly retrieved these progenitor cells to over 90 percent of fresh samples. The improved recovery of functional HPLs was reflected by their multilineage engraftment in NOD- @entity915 @entity19 . CONCLUSION: @entity7970 at 5 percent significantly ameliorates the cryopreservation of CB progenitor cells at a preclinical protocol. The increased recoveries of these cells might potentially improve the engraftment outcomes of CB transplants.

title: @entity7970 ameliorates the cryopreservation of cord blood in a preclinical system and increases the recovery of CFUs, long-term culture-initiating cells, and nonobese XXXX repopulating cells.

entities_list: @entity7970 :: ('MESH:D014199', 'Chemical') :: ['trehalose', 'Trehalose']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetic-SCID']


abstract: @entity63201 , @entity63201 , is an endemic species of China and also the only representatives of family Catostomidae in Asia. The fish was naturally distributed in Yangtze River and Mingjiang River and now few could be captured because of pollution and overexploitation. The fish has been listed in the second class of preserved animal in China. Studying and assessing its population structure is an imperative and fundamental work for making effective protection strategies. We amplified and sequenced the D-loop region of mtDNA of 8 samples. The size of the D-loop region is about 958 bp. A total of 32 variation loci were detected and the mutation rate was 0.033. All the mutation came from @entity377 substitution except one @entity377 deletion. Most of the @entity377 variations were found between the 55-365 bp region. The individual mutation rate varied from 0-1.36%, which exhibited @entity377 polymorphism to some extent among 8 samples. Compared with RAPD and other PCR-based methods, the directily sequencing of mtDNA D-loop region revealed much more genetic diversity. Meanwhile, the D-loop region of Moxostoma robustum derived from GenBank was aligned with that of @entity63201 through CLUSTAL software. By comparison, we found that the mutation rate (0.033) of D-loop of @entity63201 is higher than that of Moxostoma robustum (0.016).

title: [Genetic diversity analysis of mitochondrial D-loop region of XXXX ( @entity63201 )].

entities_list: @entity63201 :: ('70543', 'Species') :: ['Chinese sucker', 'Myxocyprinus asiaticus']

entities_list: @entity377 :: ('CHEBI:36976', 'Chemical') :: ['nucleotide']

answer: @entity63201 :: (70543,Species) :: ['Chinese sucker']


abstract: UNASSIGNED: Hormonal therapy or ketogenic diet often permits overcoming the challenging periods of many @entity302 (West and @entity5761 and @entity75 with continuous spike-waves in slow sleep), but relapse affects over 20% of @entity1 . We report here a monocenter pilot series of 42 consecutive @entity1 in whom we combined oral @entity230 with the ketogenic diet for @entity228 -resistant or -dependent @entity302 . We retrospectively evaluated the effect on @entity410 frequency, interictal spike activity, neuropsychological course, and @entity479 treatment course. Twenty-three @entity1 had @entity739 ( @entity739 ), 13 had @entity75 with continuous spike-waves in slow sleep (CSWS), and six others had miscellaneous @entity302 . All @entity1 succeeded to reach 0.8 to 1.6g/l @entity6178 bodies in the urine following the usual @entity573 regimen. For at least 6months, 14/42 responded to the addition of the ketogenic diet: 4/23 with @entity739 , 8/13 with CSWS, and 2/6 with miscellaneous @entity302 . The addition of the @entity573 allowed withdrawing @entity230 in all responders. Among them, 10/15 had been @entity1 with @entity479 -dependent @entity302 and 4/27 @entity1 with @entity479 -resistant @entity302 . Therefore, the ketogenic diet can be used successfully in combination with @entity288 for @entity302 . @entity1 presenting with @entity479 -dependent CSWS seem to be the best candidates.

title: The ketogenic diet can be used successfully in combination with XXXX for @entity302 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity5761 :: ('MESH:D065768', 'Disease') :: ['Lennox-Gastaut syndromes']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['encephalopathy']

entities_list: @entity228 :: ('CHEBI:50858', 'Chemical') :: ['corticosteroid']

entities_list: @entity739 :: ('MESH:D013036', 'Disease') :: ['WS', 'West syndrome']

entities_list: @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epileptic encephalopathy', 'epileptic encephalopathies']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

answer: @entity288 :: (MESH:D000305,Chemical) :: ['corticosteroids']


abstract: 1. @entity35 adrenal zona glomerulosa cells were incubated in Krebs Ringer bicarbonate medium containing bovine serum albumin. @entity1369 production was measured by radioimmunoassay. 2. Both [Asp1, Ile5]- @entity1808 ('free acid') and (Asn1, Val5]-antiotensin II (' @entity6346 '), (10(-5) mol/l), stimulated @entity1369 output but the free acid compound produced a larger increase in @entity134 output than the @entity6346 . 3. This difference in steroidogenic activity could not be explained by differences in purity or initial concentration or by stimulation of the contaminating fasciculata cells. 4. However, serial bioassays of the media revealed that the @entity6346 form of angiotensin was degraded more rapidly than the free acid form. 5. The different potency of these two forms of @entity1808 could explain some of the reported discrepancies of the action of @entity1808 on @entity35 adrenal tissue or cells in vitro.

title: Different potencies of [Asp1, Ile5]- and [Asn1, Val5]- @entity1808 in stimulating @entity1369 production from XXXX adrenal zona glomerulosa cells in vitro.

entities_list: @entity1369 :: ('MESH:D000450', 'Chemical') :: ['Aldosterone', 'aldosterone']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: Recent studies have found that glucocorticoids are closely associated with oncogenesis and the development of many types of @entity5 . The aim of this study was to observe the effect of @entity619 on the growth and angiogenesis of @entity65133 in @entity19 . @entity2 cells were inoculated subcutaneously into the right axilla of C57BL/6 @entity19 , and the @entity19 were randomly divided into 3 groups: the control group, @entity900 group, and @entity619 group. From day 7 after inoculation, all the @entity19 were given different treatments for 10 days, and changes in xenograft @entity5 volumes were monitored. All @entity19 were sacrificed on day 17, and the @entity5 were obtained and weighed and the @entity5 inhibitory rate was calculated. The expression levels of @entity519 inducible factor 1a ( @entity1965 ) and @entity1611 ( @entity1611 ), as well as the microvessel density (MVD) in the @entity5 mass, were measured by immunohistochemistry. @entity5 growth was suppressed in the @entity900 group and @entity619 group. The weights of @entity5 were markedly decreased in the @entity900 group and @entity619 group compared with the control group (P < 0.05). The expression levels of @entity1965 and @entity1611 and the MVD were significantly lower in the @entity900 group and @entity619 group than in the control group (P < 0.05). However, these levels were not significantly different between the @entity900 group and @entity619 group (P > 0.05). @entity619 can effectively inhibit the growth and angiogenesis of @entity2 by inhibiting the expression of @entity1965 and @entity1611 .

title: Inhibitory effect of @entity619 on Lewis XXXX @entity2 cells.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor', 'tumors']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['Lewis lung carcinoma']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity619 :: ('MESH:D003907', 'Chemical') :: ['Dexamethasone', 'dexamethasone']

entities_list: @entity65133 :: ('MESH:D018827', 'Disease') :: ['transplanted Lewis lung carcinoma']

entities_list: @entity1611 :: ('22339(Tax:10090)', 'Gene') :: ['vascular endothelial growth factor', 'VEGF']

answer: @entity19 :: (10090,Species) :: ['mice']


abstract: Rotaviruses are leading causes of @entity1902 in the young of many species. Molecular epidemiological studies in @entity1 suggest that interspecies transmission contributes to rotavirus strain diversity in @entity1 . However, population-based studies of rotaviruses in animals are few. We investigated the prevalence, risk factors for @entity281 and genetic diversity of @entity7414 in a cross-sectional survey of @entity468 housed within twenty-five rescue catteries across the UK. Morning litter tray faecal samples were collected during winter and summer 2012 from all pens containing kittens and a random sample of those housing adult @entity468 . @entity7414 RNA was detected by real-time reverse transcription polymerase chain reaction and positive samples were G and P genotyped using nested @entity63438 and @entity31463 PCR assays. A total of 1727 faecal samples were collected from 1105 pens. Overall, rotavirus prevalence was 3.0% (95% CI 1.2-4.9). 52% (13/25; CI 31.3-72.2) centres housed at least one rotavirus-positive cat. Prevalence was associated with season, odds ratio 14.8 (CI 1.1-200.4), p=0.04, but not age or @entity294 . It was higher during the summer (4.7% CI 1.2-8.3) than winter (0.8%, CI 0.2-1.5). Asymptomatic epidemics of @entity281 were detected in two centres. G genotypes were characterised for 19 (33.3%) of the 57 rotavirus positive samples and P genotypes for 36 (59.7%). Two rotavirus genotypes were identified: G3P[9] and G6P[9]. This is the first population-based study of rotavirus in @entity468 and the first report of feline G6P[9], which questions the previous belief that G6P[9] in @entity1 was of @entity291 origin.

title: Molecular epidemiology of rotavirus in UK XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'people']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhoea']

entities_list: @entity1902 :: ('MESH:D005759', 'Disease') :: ['gastroenteritis']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity7414 :: ('28875', 'Species') :: ['Group A rotavirus', 'Rotavirus A']

answer: @entity468 :: (9685,Species) :: ['cats']


abstract: @entity3236 ( @entity3236 ) is the most frequent complication following extracapsular @entity231 extraction (ECCE). To evaluate the rate of @entity3236 we examined 939 eyes (786 @entity1 ) following ECCE after a period of 26.3 months on the average. In 202 eyes (21.5%) @entity231 was associated with a clinically manifest type I or @entity6 . The overall incidence of @entity3236 was 28.1% (264 eyes). In @entity1 with no other diseases (371 eyes, 100%) it was 33.4% (124 eyes). Out of 202 eyes (100%) associated with @entity6 was seen in 21.8% (44 eyes). This difference was statistically significant (p = 0.05). Average age and sex did not differ significantly in both groups. In @entity6 @entity1 the lens epithelial cells show accumulation of @entity5121 and @entity948 which is proposed to contribute to @entity231 formation by disturbing cellular metabolism. This mechanism may explain our findings of a lower incidence of @entity3236 possibly caused by reduced proliferation of lens epithelial cells.

title: Incidence of posterior capsule opacification after extracapsular XXXX extraction in @entity6 @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['type II diabetes mellitus', 'diabetes PCO', 'diabetic']

entities_list: @entity231 :: ('MESH:D002386', 'Disease') :: ['cataract']

entities_list: @entity5121 :: ('MESH:D013012', 'Chemical') :: ['sorbitol']

entities_list: @entity948 :: ('MESH:D005632', 'Chemical') :: ['fructose']

entities_list: @entity3236 :: ('MESH:D058442', 'Disease') :: ['Posterior capsule opacification', 'PCO']

answer: @entity231 :: (MESH:D002386,Disease) :: ['cataract']


abstract: The neoplastic cells from seven @entity1 with @entity981 were studied for cell surface markers and surface morphology in the @entity4653 ( @entity4653 ). The cells were studied for surface immunoglobulin (Slg), complement receptors (EAC), receptors for cytophilic antibody (IgGEA), and nonimmune rosette formation with @entity742 red blood cells (E). In one @entity1 the cells exclusively bound E, suggesting a T-lymphocytic origin. In two @entity1 the cells bound EAC, but demonstrated no other B-lymphocytic markers. In two @entity1 no markers were detected, and in two @entity1 receptors for both E and EAC were demonstrated. Additional studies in one of these @entity1 permitted simultaneous demonstration of both markers on the same neoplastic cells. The neoplastic cells were also examined by @entity4653 after fixation and critical point dehydration. No consistent surface morphology was observed. In four @entity1 the cells were predominately smooth, whereas in two @entity1 variable numbers of surface microvilli were present. A correlation of the surface features with membrane markers could not be established. A comparison of the surface markers with clinical and cytologic features revealed clinical homogeneity in spite of the heterogeneous immunologic markers. This heterogeneity was most likely a reflection of neoplastic alteration and disordered differentiation of the cells. The observation of complement receptors on the cells of four cases is a feature not previously reported in this disease and should be investigated in other presumed T-cell @entity5 .

title: Heterogeneity of immunologic markers and surface morphology in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity981 :: ('MESH:D054198', 'Disease') :: ['childhood lymphoblastic lymphoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies']

entities_list: @entity4653 :: ('MESH:D004401', 'Disease') :: ['scanning electron microscope', 'SEM']

answer: @entity981 :: (MESH:D054198,Disease) :: ['childhood lymphoblastic lymphoma']


abstract: BACKGROUND: Self-expanding metal stents seem to be safer than conventional prostheses for palliation of malignant esophagogastric obstruction. However, recurrent @entity1282 caused by @entity5 ingrowth in uncoated types remains a problem. In addition, prior radiation and/or chemotherapy may entail an increased risk of complications. METHODS: Seventy-five @entity1 with an esophagogastric @entity189 were randomly assigned to placement of a latex prosthesis under general anesthesia or a coated, self-expanding metal stent under sedation. At entry, @entity1 were stratified for location of the @entity5 in the esophagus or @entity418 and for prior radiation and/or chemotherapy. RESULTS: Technical success and improvement in @entity1282 score were similar in both groups. Major complications were more frequent with latex prostheses (47%) than with metal stents (16%) (odds ratio 4.07: 95% CI [1.35, 12.50], p = 0.014). Recurrent @entity1282 was not different between latex prostheses (26%) and metal stents (24%). Hospital stay was longer, on average, after placement of latex prostheses than metal stents (6.3 +/- 5.2 versus 4.3 +/- 2.3 days; p = 0.043). Only prior radiation and/or chemotherapy increased the risk of specific device-related complications with respect to the esophagus (12 of 28 [43%] versus 8 of 47 [17%]; odds ratio 3.66: 95% CI [1.24, 10.82], p = 0.029). CONCLUSIONS: Coated, self-expanding metal stents are associated with fewer complications and shorter hospital stay as compared with latex prostheses, and prior radiation and/or chemotherapy increases the risk of device-related complications with respect to the esophagus.

title: Coated self-expanding metal stents versus latex prostheses for XXXX with special reference to prior radiation and chemotherapy: a controlled, prospective study.

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma']

entities_list: @entity1282 :: ('MESH:D003680', 'Disease') :: ['dysphagia']

answer: @entity5 :: (MESH:D009369,Disease) :: ['esophagogastric cancer']


abstract: PURPOSE: Radiofrequency ablation (RFA) is recommended as one of the standard treatments for @entity157 ( @entity157 ). Due to high-risk @entity5 locations unfit for RFA, transarterial chemoembolization (TACE) is served as an alternative option in these settings. To define the role of TACE on early @entity157 , we retrospectively compared the efficacies of TACE with RFA in @entity1 with unresectable BCLC stage 0/A @entity157 . MATERIALS AND METHODS: Treatment-na  ve @entity1 with unresectable BCLC stage 0/A @entity157 who underwent TACE or RFA were recruited from 2007 to 2011. In all, 208 @entity1 who underwent TACE and 235 @entity1 who underwent RFA were included in the final analysis. Using the propensity model to correct selection bias, 103 @entity1 were selected from each treatment arm. Cumulative @entity1349 ( @entity1349 ) as the primary end-point was compared after adjustment with propensity score matching (PSM). RESULTS: In all @entity1 , the @entity1349 rate was significantly higher in @entity1 treated with RFA than that in those who received TACE (1-, 3- and 5-year @entity1349 rates, 93.7%, 72.6% and 58.1% versus 88.1%, 50.3% and 30.4%, respectively; P   <   0.001). However, adjustment with PSM yielded comparable @entity1349 between the two groups (P   =   0.207). Subgroup analysis showed that RFA provided better @entity1349 than TACE in patients with serum GGT   <   75   IU/L (P   =   0.035). Univariate and subsequent multivariate analyses revealed that @entity1 -Pugh class B (HR   =   1.805; 95%CI, 1.805-3.003; P   =   0.023) and @entity3531 positivity (HR   =   2.478; 95%CI, 1.136-5.404; P   =   0.023) were independent predictors of poor prognosis. CONCLUSIONS: TACE is an effective alternative treatment for unresectable BCLC stage 0/A @entity157 when RFA is not feasible.

title: Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable BCLC stage 0/A XXXX : A propensity score matching.

entities_list: @entity1 :: ('9606', 'Species') :: ['Child', 'patients']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'early hepatocellular carcinoma']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity157 :: (MESH:D006528,Disease) :: ['HCC']


abstract: UNASSIGNED: 5078 Background: @entity25856 ( @entity25856 ) antigen is a blood group related antigen expressed in 75% of @entity43 . hu3S193 is a humanized anti- @entity25856 IgG1 mAb with strong complement dependent @entity137 and excellent targeting characteristics with a good safety profile in Phase I studies. METHODS: This phase II study accrued pts with PRR, @entity43 , @entity3906 or @entity6887 , with @entity25856 expression by IHC, <=  1 prior chemotherapy regimens in the PRR state, and a KPS >=  70%. Pts received weekly intravenous infusions (1 cycle = 8 weeks) of hu3S193 at 20mg/m(2) for up to 3 cycles, until disease progression or unacceptable @entity137 . Primary endpoint was clinical benefit rate [objective response (OR) + @entity66 ( @entity66 ) >=  24 weeks]. A two-stage design was utilized with H1 set at 15%, requiring at least 1 OR. Secondary objectives were safety, progression-free survival (PFS) and pharmacokinetics (PK). RESULTS: 31 pts were enrolled. Median age: 55 yrs (range 25-78); primary site: @entity43 -29, @entity3906 -1 @entity6887 -1; @entity25856 -positive by IHC (N): 1+ (15), 2+ (5), 3+ (8), 4+ (3). Prior @entity902 response: refractory 8, primary resistant 8, secondary resistant 14, @entity566 1; median KPS: 90% (range 70-100); median CA-125: 257 (range 18-10,041). Number of cycles of hu3S193 delivered: 32 (median 1, range <1-3). Evaluable @entity1 : 26 (5 pts < 4 doses); Responses: OR=0; @entity66 =11 (42%); @entity66 >=  24 weeks=6 (23%). No grade 4 @entity137 observed. Most frequent @entity137 in all pts (N any grade/grade 3): fatigue 4/1, @entity566 4/1, @entity400 2/1, fever 3/0, nausea 4/0, @entity101 3/0. Median PFS was 10 weeks (95 % CI, 4-15). PK data will be presented. CONCLUSIONS: single agent hu3S193 induces disease stabilization in a significant rate in this heavily pretreated population, including long term stabilization. PFS is comparable to historic chemotherapy data with acceptable @entity137 . Further studies in combination with chemotherapy are underway.

title: Anti- XXXX monoclonal antibody (mAb) hu3S193 (Rebmab 100) in @entity1 with advanced @entity902 resistant/refractory (PRR) @entity43 ( @entity43 ), @entity3906 ( @entity3906 ), or @entity6887 ( @entity6887 ).

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities', 'cytotoxicity']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['SD', 'stable disease']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']

answer: @entity25856 :: (CHEBI:59045,Chemical) :: ['LeY']


abstract: @entity146 are frequently reported in association with childhood @entity302 but the reasons for this are unclear. In a long-term prospective, community-based study of newly-diagnosed childhood @entity302 , behavioral assessments ( @entity1 Behavior Checklist) were performed in @entity1 8 to 9 years after the initial diagnosis of @entity302 to determine the impact of remission and medication status on @entity146 . @entity1 with @entity302 were also compared with sibling controls. A total of 226 @entity1 (108 females, 118 males; mean age 13y 1mo [SD 2y 8mo], range 8-17y) with @entity3762 were included in the analyses. One hundred and twenty-eight matched pairs were included in analyses of case-sibling differences. Lack of remission and current medication use were associated with worse behavioral problem and competency scores. Lack of remission generally had a greater effect than medication use, except for attention problems; medication status had the more deleterious effect (p<0.001). @entity1 with @entity302 had significantly worse @entity146 and competency scores relative to sibling controls. Even in paris in which the @entity1 was @entity410 -free and off medication, significant case-sibling differences persisted for most scales (p=0.05 to p=0.001). Lack of remission and continued use of antiepileptic drugs have a negative influence on @entity146 in @entity1 with @entity302 but do not fully explain the worse scores relative to siblings. This suggests an independent effect associated with the @entity302 itself.

title: Behavior and social competency in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Child', 'children', 'Children', 'patient']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['Behavioral and related disorders', 'behavioral problems']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

entities_list: @entity3762 :: ('MESH:C562694', 'Disease') :: ['idiopathic or cryptogenic epilepsy']

answer: @entity3762 :: (MESH:C562694,Disease) :: ['idiopathic and cryptogenic childhood epilepsy']


abstract: Objective - Educators' perceptions of the psychosocial needs of @entity645 / @entity791 orphans are important in supporting these @entity1 . The objective of this research is to determine the view of educators regarding the psychosocial needs of @entity645 / @entity791 affected @entity1 . Method - A questionnaire, based on a thorough literature study was administered to determine the views of teachers. A convenient sample of 120 teachers from different schools, who attended a workshop organised for the primary schools in a particular school district in Tswane was used. Results - Only about half of the educators indicated that their schools provided support for @entity645 / @entity791 orphans. Lack of food and clothing were viewed as the most pressing physical needs of the orphans. The desire for security, acceptance, dealing with stress, managing fears and psychological support services were identified as important psychological needs. Lack of security was seen as the most important factor affecting the psychosocial behaviour of these learners. @entity308 , sadness and stigmatisation were viewed as primary influences on behaviour. Teaching position, gender and age significantly influenced educators' views of various aspects of the learners' needs and behaviours. Conclusion - These findings have important implications for the training of educators to support learners and caregivers of @entity1 affected by the disease.

title: Educators' views on the needs and support of XXXX / @entity791 orphans in their psychosocial development.

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['Depression']

answer: @entity645 :: (57667,Species) :: ['HIV']


abstract: OBJECTIVE: Report the correlation of pre-operative findings with visual outcome in @entity235 undergoing retinal reattachment surgery for giant retinal tears. PROCEDURES: Retrospective analysis of @entity235 that underwent pars plana vitrectomy ( @entity2286 ) with silicone oil (SiO) tamponade and endolaser retinopexy at one institution. Recorded parameters included signalment, etiology, and duration of @entity1713 , observable retinal tissue architecture, visual reflexes, lens status, presurgical aqueous flare, visual status postoperatively, and complications. RESULTS: Two hundred and seventeen @entity1 (275 eyes) were included. Common etiologies of detachment were primary @entity989 (50.5%), lens surgery (35.3%), and hypermature @entity231 (6.2%). Immediate postoperative anatomic success was noted in 98% of operated eyes. Maintenance or return of vision was noted in 74.2% of @entity1 (72% of eyes) through the last known follow-up, with return of vision on average 18.5  days postoperatively. In those eyes that regained vision, 71.7% had retained vision at the last known recheck examination, with an average follow-up time of 550  days. Pre-operative findings correlated with postoperative vision included presence of a dazzle reflex, presence of a menace response, and retinal tissue architecture. The most common complications included migration of SiO into the anterior chamber (49.4%), corneal ulceration (25.7%), @entity726 (25.7%), and @entity231 formation (24.5%). CONCLUSION: Giant retinal tears in @entity235 can be successfully managed via @entity2286 with SiO tamponade and endolaser retinopexy. Vision was maintained in the majority of cases with long-term follow-up. @entity1 history and thorough ophthalmic examination with attention to retinal tissue architecture are important in assessing surgical candidacy.

title: Preoperative findings and visual outcome associated with retinal reattachment surgery in XXXX : 217 cases (275 eyes).

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patient']

entities_list: @entity231 :: ('MESH:D002386', 'Disease') :: ['cataracts', 'cataract']

entities_list: @entity1713 :: ('MESH:D012163', 'Disease') :: ['retinal detachment']

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma']

entities_list: @entity989 :: ('MESH:D012164', 'Disease') :: ['vitreoretinal disease']

answer: @entity235 :: (9615,Species) :: ['dogs']


abstract: UNASSIGNED: A 16-year-old @entity1 with no prior medical history developed vertigo and @entity390 following @entity281 . Neurological examination showed limb and @entity2055 , @entity1319 , @entity2045 , and @entity427 . Brain magnetic resonance imaging and cerebrospinal fluid analysis showed no abnormalities. Treatment with i.v. high-dose @entity1667 and immunoglobulin was started, but this proved ineffective. The clinical course was unusual, so whole-body computed tomography was done to evaluate other differential diagnoses. Imaging identified right @entity43 . Paraneoplastic @entity2055 was suspected, therefore single-incision laparoscopic ovarian cystectomy was done 10   days after admission. Two   months after therapy, the @entity1 had complete recovery and remained asymptomatic at 1   year after onset. Serum testing for anti-neuronal antibodies was negative, including for anti- @entity3391 -receptor antibody. Young @entity1 with @entity2055 and @entity1319 of unclear etiology should be examined for the presence of @entity43 , then intensive immunotherapy and prompt @entity5 resection can lead to good clinical outcome.

title: @entity2055 associated with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'girl', 'patient']

entities_list: @entity1667 :: ('MESH:D008775', 'Chemical') :: ['methylprednisolone']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian teratoma', 'ovarian mature teratoma']

entities_list: @entity2045 :: ('MESH:D009207', 'Disease') :: ['myoclonus']

entities_list: @entity3391 :: ('D016202', 'Chemical') :: ['N-methyl-d-aspartate']

entities_list: @entity1319 :: ('MESH:D015835', 'Disease') :: ['opsoclonus']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['alimentary infection']

entities_list: @entity427 :: ('MESH:D012021', 'Disease') :: ['hyperreflexia']

entities_list: @entity2055 :: ('MESH:D001259', 'Disease') :: ['opsoclonus-ataxia syndrome', 'ataxia', 'truncal ataxia']

answer: @entity43 :: (MESH:D010051,Disease) :: ['ovarian mature teratoma']


abstract: BACKGROUND: Treatment of Charcot arthopathy of the foot can be challenging. The goal of this investigation was to determine whether primary gastrocnemius-soleus recession could decrease rate of new @entity1066 , @entity85 , and amputation in @entity1 with @entity13144 of the midfoot. METHODS: A retrospective chart review revealed 28 feet in 24 @entity6 @entity1 with radiographic evidence of @entity13144 of the midfoot. They were treated with primary gastrocnemius-soleus recession. Eleven feet in 11 @entity1 had concurrent plantar midfoot @entity1066 . Three feet in 3 @entity1 were lost to follow-up. Twenty-five feet in 21 @entity1 were followed for an average of 37 months postoperatively (range = 18-79). RESULTS: A favorable outcome was defined as healing of existing @entity1066 , no new @entity1066 , no obvious @entity85 , and no amputation. Favorable outcomes were obtained in 22 of 25 feet (18 of 21 @entity1 ). Only one @entity1 had a persistent @entity1066 after gastrocnemius-soleus recession. The other 10 @entity1 with preexisting @entity1066 healed. Deformity of midfoot progressed in one @entity1 , leading ultimately to transtibial amputation. Another @entity1 developed a @entity281 and had a transfemoral amputation at another institution. DISCUSSION: These preliminary data suggest that primary gastrocnemius-soleus recession is followed by a much lower rate of persistent, recurrent, and new @entity1066 than previously reported studies. Gastrocnemius-soleus recession seems to aid in the treatment of @entity13144 of the midfoot. LEVELS OF EVIDENCE: Level IV.

title: Preliminary Results of Primary Gastrocnemius-Soleus Recession for Midfoot XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic']

entities_list: @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcer', 'ulceration', 'ulcers']

entities_list: @entity13144 :: ('MESH:D001177', 'Disease') :: ['Charcot arthropathy']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['knee joint infection']

entities_list: @entity85 :: ('MESH:D009140', 'Disease') :: ['progression of deformity']

answer: @entity13144 :: (MESH:D001177,Disease) :: ['Charcot Arthropathy']


abstract: AIMS: To estimate the relative risk of hospitalization from @entity285 -related causes among @entity1 and @entity1 in Finland across different educational categories, and to determine whether these differentials changed following a large reduction in @entity285 prices in 2004. DESIGN AND MEASUREMENTS: A register-based longitudinal study of hospitalizations. We used repeated-measures analysis to estimate @entity285 -attributable hospitalization rates and assessed effects of the reduction in @entity285 prices by comparing two 4-year periods (2000-03 and 2004-07). SETTING: Finland. @entity1 : A representative sample of the residents of Finland aged 30-79   years in the period 2000-07 (n   =   470,627). FINDINGS: There was a clear gradient across educational levels in @entity285 -attributable hospitalizations: the incidence rate ratios among @entity1 and @entity1 with basic education were 1.70 [95% confidence interval (CI)   =   1.32, 2.20] and 1.96 (95% CI   =   1.36, 2.84), respectively, compared with those with upper-tertiary education. After allowing for the long-term trend, there were no significant changes between the two follow-up periods either among @entity1 with an upper tertiary education or among @entity1 in any educational level, whereas the rate increased by 21% (95% CI   =   5, 41), 16% (95% CI   =   6, 27) and 10% (95% CI   =   2, 18), respectively, among @entity1 with a lower tertiary, secondary and basic education. However, these differences in changes were not statistically significant. CONCLUSIONS: Lower-level education is associated with a substantially increased risk of @entity285 -related hospitalization among @entity1 and @entity1 in Finland, even when adjusted for age, economic activity and income. The results do not provide strong evidence that the 2004 price reduction had differential effects by education.

title: Educational inequalities in hospitalization attributable to XXXX : a population-based longitudinal study of changes during the period 2000-07.

entities_list: @entity1 :: ('9606', 'Species') :: ['PARTICIPANTS', 'women', 'men']

answer: @entity285 :: (D000431,Chemical) :: ['alcohol']


abstract: UNASSIGNED: @entity1644 is a potentially debilitating disease that involves abnormal CSF flow mechanics; its incidence after traumatic @entity1566 ( @entity1566 ) is approximately 15%. Treatment consists of restoration of CSF flow, typically via arachnoidolysis and syrinx decompression. The authors present a case of pronounced @entity1644 in a @entity1 with concomitant severe cervical myelomalacia to demonstrate unilateral @entity327 palsy as a potential complication of @entity146 at a remote level. A 56-year-old @entity1 with a remote history of @entity1566 at T-11 (ASIA [American @entity3510 Association] Grade A) presented with complaints of ascending motor and sensory weakness into the bilateral upper extremities that had progressed over 1 year. MRI demonstrated severe distortion of the spinal cord at the prior injury level of T10-11, where an old anterior @entity130 and prior hook-rod construct was visualized. Of note, the @entity1 had a holocord syrinx with demonstrable myelomalacia. To restore CSF flow and decompress the spinal cord, T-2 and T-3 laminectomies, followed by arachnoidolysis and syringopleural shunt placement, were performed. Postoperatively on Day 1, with the exception of a unilateral deltoid palsy, the @entity1 had immediate improvement in @entity2045 strength and @entity602 . He was discharged from the hospital on postoperative Day 5; however, at his 2-week follow-up visit, a persistent unilateral deltoid palsy was noted. MRI demonstrated a significant reduction in the holocord syrinx, no @entity1274 , and a significant positional shift of the ventral spinal cord. Further motor recovery was noted at the 8-month follow-up. @entity1644 is a debilitating disease arising most often as a result of traumatic @entity1566 . In the setting of myelomalacia with a pronounced syrinx, @entity327 palsy is a potential complication of syrinx decompression.

title: XXXX palsy after cerebrospinal fluid diversion in posttraumatic @entity1644 : case report.

entities_list: @entity3510 :: ('MESH:D013124', 'Disease') :: ['Spinal Injury']

entities_list: @entity1644 :: ('MESH:D013595', 'Disease') :: ['syringomyelia', 'Syringomyelia']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressive syrinx decompression']

entities_list: @entity2045 :: ('MESH:D009207', 'Disease') :: ['upper-extremity']

entities_list: @entity602 :: ('MESH:D013118', 'Disease') :: ['myelopathy']

entities_list: @entity1274 :: ('MESH:D006319', 'Disease') :: ['neural foraminal stenosis']

entities_list: @entity1566 :: ('MESH:D013119', 'Disease') :: ['spinal cord injury', 'SCI']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['column injury']

answer: @entity327 :: (727,Gene) :: ['C-5']


abstract: OBJECTIVE: The aim of the present study was to evaluate perioperative outcomes in initial experiences of robot-assisted laparoscopic radical cystectomy (RARC) in comparison with those of laparoscopic radical cystectomy (LRC) for muscle-invasive or high-risk non- @entity150 . METHODS: We performed RARC on six @entity1 with muscle-invasive or high-risk non- @entity150 starting in October 2011. During the same period, another five @entity1 underwent LRC. Perioperative outcomes in initial experiences of RARC were elucidated by comparing them with those of LRC. RESULTS: Robot-assisted procedures were completed in all cases without conversion to open surgery. The median time of @entity516 was 252 minutes, and the median @entity190 was 340 mL. No severe complications were observed. Perioperative outcomes did not significantly differ between RARC and LRC. Although two cases of troubles in uretero-conduit anastomosis sites were observed after LRC, no @entity1 experienced @entity260 related to urinary diversion after RARC. CONCLUSIONS: Our data indicate that RARC is an acceptable option even in the initial period, and it may become one of the most favorable procedures for treatment of @entity150 in the near future, although more tests and longer follow-ups are required to confirm its effectiveness and safety.

title: Comparison of initial experiences of robot-assisted radical cystectomy with those of laparoscopic for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['postoperative complication']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['muscle-invasive bladder cancer']

entities_list: @entity516 :: ('MESH:D011027', 'Disease') :: ['pneumoperitoneum']

answer: @entity150 :: (MESH:D001749,Disease) :: ['bladder cancer']


abstract: PURPOSE: Since receiving a warning from the US Food and Drug Administration (FDA) about injection of @entity288 into the epidural space having serious adverse events, we have sought alternative medications for injection at this site. @entity7245 ( @entity7245 ) has anti-adhesive, anti-inflammatory, and lubricating properties, so could potentially be useful for spinal @entity158 . The exact mechanism by which @entity612 develops is not fully understood, but is likely to involve @entity32 . Therefore, we hypothesized that @entity7245 could have a therapeutic effect in @entity612 . This study evaluated the effects of epidural administration of @entity7245 on alleviation of @entity158 in a rat model of @entity850 . MATERIALS AND METHODS: After creating the animal model, @entity7245 ( @entity7245 group) or saline solution (S group) was administered via an epidural catheter. The paw-withdrawal threshold to mechanical stimulation and motor dysfunction were monitored for up to 21 days. Tissue was collected to evaluate the degree of @entity1104 , @entity32 in the perineural area, and chromatolysis in the dorsal root ganglion (DRG). RESULTS: The mechanical withdrawal threshold was restored in the @entity7245 group but not in the S group (P < 0.001). The @entity7245 group also showed less @entity82 (P = 0.026) and less chromatolysis (P = 0.002) than the S group. CONCLUSION: @entity7245 administered epidurally had a therapeutic effect on the @entity1931 and @entity1931 induced by chronic compression of the DRG.

title: Therapeutic effect of epidural hyaluronic acid in a rat model of XXXX .

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis']

entities_list: @entity1931 :: ('MESH:D006930', 'Disease') :: ['allodynia', 'hyperalgesia']

entities_list: @entity7245 :: ('MESH:D000592', 'Disease') :: ['Hyaluronic acid', 'HA']

entities_list: @entity612 :: ('MESH:D013130', 'Disease') :: ['spinal stenosis']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['foraminal stenosis']

entities_list: @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']

answer: @entity850 :: (MESH:D003251,Disease) :: ['foraminal stenosis']


abstract: Glycemic control is often difficult to achieve in @entity1 with @entity6 , especially in the presence of comorbid diseases or conditions such as @entity134 -use or liver @entity82 , or in @entity1 receiving enteral nutrition. Moreover, reactive @entity4053 due to late dumping syndrome in @entity1 having undergone gastrectomy is also a matter of concern. Empirically and theoretically, the typical glycemic profiles associated with these conditions have been determined; however, what actually happens during a 24-h span is still somewhat obscure. In order to verify and provide information about the 24-h glycemic profiles associated with these conditions, 8 @entity1 with the 4 above-mentioned conditions were monitored using a continuous @entity413 monitoring system (CGMS). For all 8 @entity1 , CGMS provided detailed information regarding the 24-h glycemic profiles. The CGM results showed typical glycemic patterns for each condition, and we were moreover able to observe the effects of various practical treatments. Based on these cases, we conclude that the CGMS is highly useful for determining the glycemic patterns of @entity1 with the aforementioned conditions in a practical setting; and this system may be used to monitor the treatment success of such cases. J. Med. Invest. 62: 1-10, February, 2015.

title: Verification of glycemic profiles using continuous XXXX monitoring: cases with @entity134 use, liver @entity82 , enteral nutrition, or late dumping syndrome.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'people']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity4053 :: ('MESH:D007003', 'Disease') :: ['hypoglycemia']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity413 :: (MESH:D005947,Chemical) :: ['glucose']


abstract: Delivery of suicide genes to @entity5 represents a promising @entity5 therapy strategy. However, slow or limited killing by suicide genes and ineffective targeting of the @entity5 has reduced effectiveness. We have adapted a suicide system based on an inducible @entity8187 (iC9) protein that is activated using a specific @entity576 ( @entity576 ) for adenoviral-based @entity2 via mesenchymal stromal cells (MSCs). Four independent @entity1 @entity1149 ( @entity1149 ) cell lines were transduced with adenovirus encoding iC9, and all underwent apoptosis when iC9 was activated by adding @entity576 . However, there was a large variation in the percentage of cell killing induced by @entity576 across the different lines. The least responsive cell lines were sensitized to apoptosis by combined inhibition of the proteasome using @entity1749 . These results were extended to an in vivo model using @entity1 @entity1149 xenografts. E1A-expressing MSCs replicated Ad.iC9 and delivered the @entity2 in @entity915 @entity19 . Treatment with @entity576 resulted in some reduction of @entity5 growth, but addition of @entity1749 led to greater reduction of @entity5 size. The enhanced apoptosis and anti- @entity5 effect of combining MSC-delivered Ad.iC9, @entity576 and @entity1749 appears to be due to increased stabilization of active @entity522 , as proteasomal inhibition increased the levels of cleaved @entity8187 and @entity522 . Knockdown of @entity9846 ( @entity9846 ), a caspase inhibitor that targets active @entity522 to the proteasome, also sensitized iC9-transduced cells to @entity576 , suggesting that blocking the proteasome counteracts @entity9846 to permit apoptosis. Thus, MSC-based delivery of the iC9 suicide gene to @entity1 @entity1149 effectively targets @entity2 cells for elimination. Combining this therapy with @entity1749 , a drug that is otherwise inactive in this disease, further enhances the anti- @entity5 activity of this strategy. @entity5 Gene Therapy advance online publication, 17 October 2014; doi:10.1038/cgt.2014.53.

title: @entity1749 sensitizes @entity1149 to mesenchymal stromal cell-delivered inducible XXXX -mediated cytotoxicity.

entities_list: @entity576 :: ('MESH:D064419', 'Disease') :: ['CID', 'chemical inducer of dimerization']

entities_list: @entity9846 :: ('331', 'Gene') :: ['XIAP', 'X-linked inhibitor of apoptosis protein']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Cancer', 'solid tumors']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['delivery to lung tumors', 'lung cancer', 'virus to lung tumors']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']

entities_list: @entity1749 :: ('MESH:C400082', 'Chemical') :: ['bortezomib']

answer: @entity8187 :: (842,Gene) :: ['caspase-9']


abstract: OBJECTIVE: The purpose of this study was to determine the effects of a 4-week auricular point acupressure (APA) treatment on @entity1643 ( @entity1643 ) outcomes and examine the day-to-day variability of @entity1643 in individuals receiving APA for @entity1643 over 29 days. DESIGN: This was a prospective, randomized controlled trial (RCT). Data were collected at baseline, during each of the four office visits for APA treatment, after the completion of the 4-week intervention, and 1 month after the last treatment. A daily diary was given to each @entity1 to record his or her APA practices, analgesic use, and @entity158 intensity. INTERVENTIONS: APA was used to manage @entity1643 . The @entity1 received one APA treatment per week for 4 weeks. @entity1 AND SETTING: Sixty-one @entity1 with @entity1643 were randomized into either a real APA or sham APA treatment group. @entity1 were recruited from primary care offices and clinics or through the Research @entity1 Registry at the University of Pittsburgh. RESULTS: Among @entity1 in the real APA group, a 30% reduction of worst @entity158 was exhibited after the first day of APA treatment, and continuous reduction in @entity158 (44%) was reported by the completion of the 4-week APA. This magnitude of @entity158 reduction reached the clinically significant level of improvement reported in other clinical trials of chronic @entity158 therapies. Analgesic use by @entity1 in the real APA group also was reduced compared with use by @entity1 in the sham group. CONCLUSION: This study shows that APA is a promising @entity158 management strategy that is not invasive and can be self-managed by @entity1 for @entity1643 . Given the day-to-day fluctuation in ratings, the tighter ecologic assessment of @entity158 scores and other treatment parameters are an important pragmatic aspect of the design of chronic @entity158 studies.

title: Day-to-Day Changes of Auricular Point Acupressure to Manage XXXX : A 29-day Randomized Controlled Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'participant', 'PATIENTS', 'Participant', 'Participants']

entities_list: @entity1643 :: ('MESH:D017116', 'Disease') :: ['chronic low back pain', 'CLBP']

answer: @entity1643 :: (MESH:D017116,Disease) :: ['Chronic Low Back Pain']


abstract: A 72-year-old female was referred to our hospital for evaluation of a hyperechoic mass in the pancreatic head with ultrasound sonography. She had no symptom expect slight @entity417 (Hb 11.3  g/dl). On endoscopy, blood was expelled from the orifice of the major @entity9317 , but excretion of mucus was not detected. Endoscopic retrograde pancreatography revealed an irregular defect in the main pancreatic duct at the head of the pancreas. Computed tomography revealed a 2-cm mass with a low density lesion in the pancreas head. On suspicion of @entity5 , pylorus-preserving pancreaticoduodenectomy was performed. Histological diagnosis was @entity1377 without @entity3558 hypersecretion. It grew within the inferior branch of the main @entity788 stood out into the main pancreatic duct. As the causes of hemosuccus pancreaticus, pancreatic benign diseases, for example, chronic @entity788 , @entity438 and @entity2849 , are known, but @entity788 are rare. In particular, this may be the first report of hemosuccus pancreaticus induced by @entity1377 of the pancreas without @entity3558 hypersecretion.

title: Hemosuccus pancreaticus due to XXXX of the pancreas.

entities_list: @entity1377 :: ('MESH:D002291', 'Disease') :: ['intraductal papillary-mucinous carcinoma']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic duct, and the top of the tumor', 'pancreatitis', 'pancreatic tumors']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignant tumor of the pancreas']

entities_list: @entity2849 :: ('MESH:D017541', 'Disease') :: ['pseudoaneurysm']

entities_list: @entity9317 :: ('MESH:D004382', 'Disease') :: ['duodenal papilla']

entities_list: @entity438 :: ('MESH:D002532', 'Disease') :: ['pseudocyst, arterial aneurysm']

answer: @entity1377 :: (MESH:D002291,Disease) :: ['intraductal papillary-mucinous carcinoma']


abstract: Inhibition of the enzyme aromatase, the rate limiting step in @entity172 production, is an effective endocrine treatment of advanced @entity0 . Recently, several new aromatase inhibitors have been developed to improve efficacy and reduce @entity137 compared to the prototype aromatase inhibitor @entity6239 . Aromatase inhibitors can be divided into two types. The first are the non-steroidal inhibitors that have a mechanism of action similar to @entity6239 . The second are the steroidal inhibitors that function as a false substrate for aromatase. Of the non-steroidal aromatase inhibitors, two drugs, @entity13558 and @entity4672 , have recently been registered for the second line endocrine treatment of advanced @entity0 after failure on @entity440 . The phase III studies of these drugs indicate at least equal efficacy compared to current second line treatment with @entity6239 or @entity6303 . Their @entity137 profile, however, is much more favourable. This makes them the drugs of choice for the second line endocrine treatment of advanced @entity0 in postmenopausal @entity1 , who failed during adjuvant or first line treatment with @entity440 . Of the steroidal aromatase inhibitors, the orally active drug @entity17082 is still in phase III clinical study; the registration is expected in 1999.

title: New aromatase inhibitors for the treatment of advanced @entity0 in postmenopausal XXXX .

entities_list: @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity4672 :: ('MESH:C067431', 'Chemical') :: ['letrozole']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['postmenopausal breast cancer', 'breast cancer']

entities_list: @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen']

entities_list: @entity6239 :: ('MESH:D000616', 'Chemical') :: ['aminoglutethimide']

entities_list: @entity17082 :: ('MESH:C056516', 'Chemical') :: ['exemestane']

entities_list: @entity6303 :: ('MESH:D019290', 'Chemical') :: ['megestrol acetate']

entities_list: @entity13558 :: ('MESH:C090450', 'Chemical') :: ['anastrozole']

answer: @entity1 :: (9606,Species) :: ['women']


abstract: STUDY DESIGN: Prospective clinical study. OBJECTIVE: To test whether elastic stabilization with the Dynesys system (Zimmer Spine, Minneapolis, MN) provides enough stability to prevent further progression of spondylolisthesis as well as instability after decompression for @entity612 with @entity179 . SUMMARY OF BACKGROUND DATA: In @entity612 with @entity179 , decompression and fusion is widely recommended. However, @entity1 have donor site @entity158 . In 1994, a dynamic transpedicular system (Dynesys) was introduced to the market, stating that stabilization is possible without bone grafting. METHODS: A total of 26 @entity1 (mean age 71 years) with @entity2649 and @entity179 underwent interlaminar decompression and dynamic stabilization with the Dynesys system. Minimum follow-up was 2 years. Operative data, clinical outcome, and plain and flexion/extension radiographs were obtained and compared to preoperative and postoperative data. RESULTS: Mean @entity158 decreased significantly (P < 0.01), and mean walking distance improved significantly to more than 1000 m (P < 0.01). There were 5 @entity1 (21%) who still had some @entity613 . A total of 21 @entity1 (87.5%) would undergo the same procedure again. Radiographically, no significant progression of spondylolisthesis could be detected. The implant failure rate was 17%, and none of them were clinically symptomatic. CONCLUSIONS: In elderly @entity1 with @entity612 with @entity179 , dynamic stabilization with the Dynesys system in addition to decompression leads to similar clinical results as seen in established protocols using decompression and fusion with pedicle screws. It maintains enough stability to prevent further progression of spondylolisthesis or instability. With the Dynesys system, no bone grafting is necessary, therefore, donor site morbidity can be avoided.

title: Dynamic stabilization in addition to decompression for @entity2649 with XXXX .

entities_list: @entity612 :: ('MESH:D013130', 'Disease') :: ['spinal stenosis']

entities_list: @entity2649 :: ('MESH:C563613', 'Disease') :: ['lumbar spinal stenosis']

entities_list: @entity613 :: ('MESH:D007383', 'Disease') :: ['claudication']

entities_list: @entity179 :: ('MESH:D019636', 'Disease') :: ['degenerative spondylolisthesis']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'leg pain']

answer: @entity179 :: (MESH:D019636,Disease) :: ['degenerative spondylolisthesis']


abstract: UNASSIGNED: We evaluated temporal fluctuations in @entity7646 resistance rates, analyzing genetic determinants of resistance and @entity2214 in a population of 2744 @entity4195 isolates collected in the period 2000-2013. The total resistance rate to @entity2929 of the isolates was 17.9%. A maximum of @entity2929 resistance emerged in 2000 (38.6%), followed by a significant decrease to 5.2% in 2012 (p<0.0001). Molecular analysis revealed the presence and co-presence of known genetic resistance determinants mefA, mefE, ermTR and ermB, in line with phenotypes. PFGE analysis identified genetically related groups in 2000 and 2007-2008, mainly @entity32489 and M phenotypes, respectively. The most prevalent emm types among a representative subset of resistant isolates were emm2, emm75 and emm77. All emm2 and 88.2% of the strains harboring the emm75 gene were only recorded in M phenotype strains, while all emm77-positive strains had the inducible @entity32489 phenotype. Analyzed susceptible isolates showed several emm types partially shared with resistant ones. Our results suggest that changes in bacterial population clonality rather than horizontal transfer of resistance determinants play a major epidemiological role. Continuous monitoring of microbiological epidemiology seems to be crucial for correct and effective management of @entity883 .

title: Evolution of @entity7646 resistance in XXXX over 14-years in an area of central Italy.

entities_list: @entity2214 :: ('MESH:D007945', 'Disease') :: ['clonal evolution']

entities_list: @entity883 :: ('MESH:D013290', 'Disease') :: ['streptococcal infections']

entities_list: @entity7646 :: ('CHEBI:25106', 'Chemical') :: ['macrolide']

entities_list: @entity2929 :: ('MESH:D004917', 'Chemical') :: ['erythromycin']

answer: @entity4195 :: (1314,Species) :: ['Streptococcus pyogenes']


abstract: BACKGROUND: No epidemiological data on prevalence rates of @entity146 based on a representative sample are available for Austrian adolescents up to now. However, the knowledge of @entity146 , related risk and protective factors is of great significance for treatment and prevention. The purpose of the @entity1032 -Study ( @entity1032 ), the first epidemiological study on mental health in Austria, is to obtain prevalence rates of @entity146 and to examine risk factors, protective factors and quality of life in a representative sample of adolescents aged 10-18. Aims of this pilot study were to evaluate the feasibility and acceptability of the screening instruments, pre-estimate the frequency of mental health problems and estimate possible non-responder bias. METHODS: Twenty-one schools in eastern Austria were asked to participate. Data on mental health problems were derived from self-rating questionnaires containing standardized screening measures (Youth Self-Report, measuring emotional and @entity146 and the SCOFF, indicating eating problems. Quality of life as well as related risk and protective factors were also obtained. RESULTS: Four hundred and eight adolescents of five schools were recruited. The prevalence of mental health problems was 18.9  % [CI 95  %: 14.9-22.7]. Moreover, emotional and @entity146 were highly correlated with quality of life measures. A Non-Responder Analysis indicated that non-responders (16.7  %) differ from responders with regard of school related problems. CONCLUSIONS: The results demonstrate that mental health problems affect approximately one fifth of the adolescents. A Non-Responder Analysis suggests that the prevalence of @entity146 is underestimated.

title: The XXXX ( @entity1032 )-Study: preliminary results from a pilot study.

entities_list: @entity1032 :: ('MESH:D008607', 'Disease') :: ['MHAT', 'Mental Health in Austrian Teenagers']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['mental disorders', 'behavioral problems', 'behavioral and emotional problems', 'psychiatric disorders']

answer: @entity1032 :: (MESH:D008607,Disease) :: ['Mental Health in Austrian Teenagers']


abstract: OBJECTIVE: To conduct a systematic review and meta-analysis of clinical trials involving adults, to determine the effect of @entity353 induced by energy restriction with or without exercise, antiobesity drugs or bariatric surgery on pulse wave velocity ( @entity122 ) measured at all arterial segments. APPROACH AND RESULTS: A systematic search of Pubmed (1966 to 2014), EMBASE (1947 to 2014), MEDLINE (1946 to 2014), and the Cochrane Library (1951 to 2014) was conducted and the reference lists of identified articles were searched to find intervention trials (randomized/nonrandomized) that aimed to achieve @entity353 and included @entity122 as an outcome. The search was restricted to @entity1 studies. Two independent researchers extracted the data. Data were analyzed using Comprehensive Meta Analysis version 2 using random effects analysis. A total of 22 studies were included in the qualitative synthesis and 20 studies (3 randomized controlled trials), involving 1259 @entity1 , were included in the meta-analysis. The standardized mean difference for the overall effect of @entity353 on @entity122 measured at all sites was -0.32 (95% confidence interval, -0.41, -0.24; P=0.0001). Carotid femoral pulse wave velocity (standardized mean difference, -0.35; 95% confidence interval, -0.44, -0.26; P=0.0001; 16 studies) and brachial ankle @entity122 (standardized mean difference, -0.48; 95% confidence interval, -0.78, -0.18; P=0.002; 5 studies) were improved with @entity353 . Meta-regression showed that change in blood pressure was a predictor of change in @entity122 (P<0.01). CONCLUSION: Modest @entity353 (mean 8% of initial body weight) achieved with diet and lifestyle measures improved @entity122 . The results of this meta-analysis suggest that @entity353 may reduce @entity122 , although future research is required.

title: Effect of XXXX on pulse wave velocity: systematic review and meta-analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'participants']

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss']

answer: @entity353 :: (MESH:D015431,Disease) :: ['weight loss']


abstract: OBJECTIVE: @entity1 with @entity735 movement @entity25 (RBD) are at substantial risk for developing @entity191 ( @entity191 ) or related @entity179 . Speech is an important indicator of motor function and movement coordination, and therefore may be an extremely sensitive early marker of changes due to @entity179 . METHODS: Speech data were acquired from 16 RBD subjects and 16 age- and sex-matched healthy control subjects. Objective acoustic assessment of 15 speech dimensions representing various phonatory, articulatory, and prosodic deviations was performed. Statistical models were applied to characterise @entity8408 in RBD and to estimate sensitivity and specificity in differentiating between RBD and control subjects. RESULTS: Some form of @entity73 was revealed in 88% of RBD subjects. @entity51 were the most prominent findings in RBD. In comparison to controls, the RBD group showed significant alterations in irregular alternating motion rates (p   =   0.009) and articulatory decay (p   =   0.01). The combination of four distinctive speech dimensions, including aperiodicity, irregular alternating motion rates, @entity1547 , led to 96% sensitivity and 79% specificity in discriminating between RBD and control subjects. Speech impairment was significantly more pronounced in RBD subjects with the motor score of the Unified @entity191 Rating Scale greater than 4 points when compared to other RBD individuals. CONCLUSION: Simple quantitative speech motor measures may be suitable for the reliable detection of @entity179 in subjects with RBD, and therefore may provide important outcomes for future therapy trials.

title: Quantitative assessment of motor speech abnormalities in @entity735 movement XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['speech impairment']

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease", "Parkinson's Disease", 'PD']

entities_list: @entity735 :: ('MESH:D005124', 'Disease') :: ['idiopathic rapid eye']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['Articulatory deficits']

entities_list: @entity1547 :: ('MESH:D003731', 'Disease') :: ['articulatory decay, and dysfluency']

entities_list: @entity179 :: ('MESH:D019636', 'Disease') :: ['prodromal neurodegeneration', 'neurodegenerative disorders']

entities_list: @entity8408 :: ('MESH:D013064', 'Disease') :: ['speech disorders']

entities_list: @entity25 :: ('MESH:D012893', 'Disease') :: ['sleep behaviour disorder']

answer: @entity25 :: (MESH:D012893,Disease) :: ['sleep behaviour disorder']


abstract: OBJECTIVE: To develop a new treatment for advanced @entity3123 . METHODS: Twenty-nine @entity1 with advanced @entity3123 (12 @entity1 with liver @entity3 at the same time) were randomly divided into two groups. In group A (n = 11), @entity1 underwent @entity354 combined with systemic chemotherapy after surgery. In group B (n = 18), @entity1 underwent @entity354 combined with peripancreatic arterial ligation and arterial infusion regional chemotherapy. Twenty-four @entity1 were followed up for 3 - 18 months. The palliation of clinical symptoms, changes in @entity189 size by B ultrasound (BUS) and CT scan, survival period and serum @entity787 ( @entity787 ) were observed and compared between the two groups. RESULTS: Symptoms were alleviated in most @entity1 in group B, and BUS and CT scan showed that @entity5 volume decreased in group B. The response rate was 66.7% in group B and 18.2% in group A (P < 0.01). The mean survival period was 4.8 +/- 0.6 months in group A and 12.5 +/- 1.2 months in group B (P < 0.01); there were significant differences between the two groups. The decrease in serum @entity787 was 54% in group A and 60% in group B; the difference was not significant (P > 0.05). CONCLUSION: Peripancreatic arterial ligation combined with arterial infusion regional chemotherapy is effective against both @entity3123 and with liver metastases. It can alleviate clinical symptoms, postpone the growth rate of @entity5 and prolong the survival period.

title: Peripancreatic artery ligation and artery infusion chemotherapy for advanced XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity3123 :: ('MESH:C562463', 'Disease') :: ['pancreatic carcinoma']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma']

entities_list: @entity787 :: ('1084', 'Gene') :: ['CEA', 'carcinoembryonic antigen']

entities_list: @entity354 :: ('MESH:D005764', 'Disease') :: ['bilio-enterostomy and/or gastro-enterostomy']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

answer: @entity3123 :: (MESH:C562463,Disease) :: ['pancreatic carcinoma']


abstract: BACKGROUND: di @entity35607 ( @entity5248 ) is widely used in the plastic industry and can induce reproductive @entity137 . On the other hand, @entity6211 (LC) plays a crucial role in sperm metabolism and maturation. This study evaluates the effect of LC on body and testis weight, testis tissue, count, motility, viability, morphology, and chromatin quality of epididymal sperm, @entity10523 ( @entity10523 ) per gram testis and daily sperm production (DSP) in LC-treated @entity19 . MATERIALS AND METHODS: IN THIS EXPERIMENTAL STUDY, ADULT MALE NMRI @entity19 (MEAN AGE: 4 weeks) were given doses of @entity5248 and LC by gavaging for 2 weeks. All samples were assessed according to World Health Organization (WHO) criteria. Sperm morphology was assessed using Papanicolaou staining and sperm chromatin quality by @entity9308 -blue staining. The left testes were fixed in Bouin   solution for histological examination and the end slices were stained with @entity1710 and @entity1711 (H_E). The right testes were homogenized, and then @entity10523 and DSP were calculated with an improved Neubauer haemocytometer and respective frames. Paired t-test, ANOVA, and Kruskal-Wallis tests were utilized for data analysis. RESULTS: Co-administration of @entity5248 and LC not only prevented significant gains in testicular weight, but also maintained the sperm's normal morphology and chromatin quality (p<0.05). In addition, LC recovered histological changes, @entity10523 , DSP, and sperm count. CONCLUSION: These results demonstrated that oral administration of LC partially or generally protects spermatogenesis from @entity5248 - @entity137 in @entity19 .

title: Prevention of di @entity35607 -induced Testicular Disturbance in @entity19 by Co-administration of XXXX .

entities_list: @entity10523 :: ('MESH:D013733', 'Disease') :: ['TSN', 'testicular spermatid number']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity6211 :: ('MESH:D002331', 'Chemical') :: ['L-carnitine']

entities_list: @entity35607 :: ('CHEBI:17243', 'Chemical') :: ['(2-ethylhexyl) phthalate']

entities_list: @entity1710 :: ('MESH:D006416', 'Chemical') :: ['hematoxylin']

answer: @entity6211 :: (MESH:D002331,Chemical) :: ['L-carnitine']


abstract: Even though the majority of actions undertaken within the secondary prevention of @entity299 should be initiated while the @entity1 is still hospitalized, the maximum benefit (measured as decreased cardiovascular risk) achieved depends mostly on the continuation and modification of these actions in the postdischarge period. There is not much known about the quality of medical care provided for @entity1 after hospitalization due to @entity299 . The aim of the study was to assess the quality of postdischarge care in the field of secondary prevention of @entity299 . METHODS: Consecutive @entity1 (age > or = 70 years; residing in the Cracow province) were identified according to the following clinical diagnoses or procedures: acute @entity583 , @entity1459 , CABG and PCI. Out of 536 @entity1 418 took part in the control visit 6-18 months after discharge. Risk factors and medication used were assessed. RESULTS: High total @entity165 (> or = 5.2 mmol/l) was found in 65.8% of @entity1 , @entity101 (> or = 140/90 mmHg) in 46.2%, @entity28 (BMI > or = 30 kg/m2) in 24.6%, fasting @entity413 over 6.0 mmol/l in 17.7% and smoking in 16.3%. The frequency of antiplatelet drugs and beta-blockers use decreased whereas that of lipid-lowering drugs increased in the postdischarge period. The highest frequency of use of antiplatelets and lipid-lowering drugs, as well as the best control of @entity1007 was found in the PCI group, whereas the lowest frequency of smoking was found in the CABG group. CONCLUSIONS: Insufficient control of risk factors and the frequency of secondary prevention using drugs was found. There is a need to intensify secondary prevention in @entity1 with @entity299 in the postdischarge period.

title: [Krakow Program for Secondary Prevention of @entity299 . Part III. Secondary prevention of XXXX after discharge].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['high blood pressure']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

entities_list: @entity1007 :: ('MESH:D006937', 'Disease') :: ['hypercholesterolemia']

entities_list: @entity1459 :: ('MESH:D000789', 'Disease') :: ['unstable angina']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['ischaemic heart disease']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity299 :: (MESH:D006331,Disease) :: ['ischaemic heart disease']


abstract: BACKGROUND: With a prevalence of 3 to 8% among @entity1 of reproductive age, severe @entity1109 are very common. Symptoms range from emotional and cognitive to physical changes. Severe symptoms (that is, @entity3010 ) can have a strong impact on everyday functioning and quality of life. Impairment can be as serious as that of @entity14256 . Many affected @entity1 receive either no treatment at all or are unsatisfied with their treatment. Although there is some evidence for the @entity147 through cognitive behavioural therapy, there are only a small number of randomised controlled trials carefully investigating the efficacy of this psychotherapeutic approach. Thus, this study aims to evaluate the efficacy of a cognitive behavioural self-help treatment for @entity1 suffering from @entity3010 . METHODS/DESIGN: The study is conducted as a randomised controlled trial. The complex diagnostic assessment includes the completion of a symptom diary over two consecutive cycles and a telephone interview. Eligible @entity1 are randomly assigned to either a treatment or a wait-list control group. The intervention is based on cognitive behavioural therapy principles and is provided via the internet. It consists of 14 different modules on which @entity1 work over 8 consecutive weeks. In addition to written information, @entity1 receive email feedback from a clinical psychologist on a weekly basis. @entity1 assigned to the wait-list receive the treatment after the end of the waiting period (8  weeks). The primary outcome measure is the @entity3010 Impairment Measure. Secondary outcomes include the @entity3010 Coping Measure, the Short-Form Social Support Questionnaire, the Questionnaire for the Assessment of Relationship Quality, and the Perceived Stress Scale. Data is collected during the premenstrual (luteal) phase at pre-treatment, post-treatment, and 6-month follow-up. DISCUSSION: So far, there is no study investigating internet-based cognitive behavioural therapy for @entity3010 . The programme approaches the problem of high prevalence in combination with severe @entity73 . TRIAL REGISTRATION: ClinicalTrials.gov: NCT01961479, 9 October 2013.

title: Internet-based cognitive behavioural self-help for XXXX : study protocol for a randomised controlled trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'Participants']

entities_list: @entity14256 :: ('MESH:D019263', 'Disease') :: ['dysthymic disorders']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['impairment and insufficient treatment options']

entities_list: @entity1109 :: ('MESH:D012678', 'Disease') :: ['premenstrual symptoms']

entities_list: @entity147 :: ('MESH:D005316', 'Disease') :: ['reduction of distress']

entities_list: @entity3010 :: ('MESH:D011293', 'Disease') :: ['Premenstrual Syndrome', 'premenstrual syndrome']

answer: @entity3010 :: (MESH:D011293,Disease) :: ['premenstrual syndrome']


abstract: Decreased circulating protein C and increased circulating @entity9820 are markers of the prothrombotic, antifibrinolytic state associated with poor outcomes in @entity295 but have not been measured in @entity1 with @entity647 ( @entity647 )/ @entity649 ( @entity649 ). We measured circulating and intra-alveolar protein C and @entity9820 in 45 @entity1 with @entity647 / @entity649 from septic and nonseptic causes and correlated the levels with clinical outcomes. Plasma protein C levels were lower in @entity647 / @entity649 compared with normal. Lower levels of protein C were associated with worse clinical outcomes, including death, fewer ventilator-free days, and more nonpulmonary organ failures, even when only @entity1 without @entity295 were analyzed. Levels of @entity9820 in @entity3126 fluid from @entity647 / @entity649 @entity1 were >10-fold higher than normal plasma and 2-fold higher than @entity647 / @entity649 plasma. Higher @entity4 fluid @entity9820 levels were associated with worse clinical outcomes. The higher levels in @entity4 fluid compared with plasma suggest local release of soluble @entity9820 in the lung, possibly from a lung epithelial source. To determine whether lung epithelial cells can release @entity9820 , A549 cells and primary isolates of @entity1 alveolar type II cells were exposed to @entity274 or inflammatory cytokines. Both epithelial cell types released @entity9820 into the media. In summary, the protein C system is markedly disrupted in @entity1 with @entity647 / @entity649 from both septic and nonseptic causes. The protein C system may be a potential therapeutic target in @entity1 with @entity647 / @entity649 .

title: Protein C and XXXX in @entity1 @entity647 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'human']

entities_list: @entity3126 :: ('MESH:D011654', 'Disease') :: ['pulmonary edema']

entities_list: @entity649 :: ('MESH:D012128', 'Disease') :: ['ARDS', 'acute respiratory distress syndrome']

entities_list: @entity9820 :: ('7056', 'Gene') :: ['thrombomodulin']

entities_list: @entity647 :: ('MESH:D055371', 'Disease') :: ['acute lung injury', 'ALI']

answer: @entity9820 :: (7056,Gene) :: ['thrombomodulin']


abstract: BACKGROUND: The median survival for @entity1 with stage IV @entity320 is usually limited to approximately 1 year. In the case of liver @entity3 , resection and ablation can achieve long-term survival. This study aimed to describe the outcomes after liver resection or ablation for @entity320 to the liver and identify preoperative prognostic factors. METHODS: Forty eight @entity1 who underwent liver resection (n   =   32) or percutaneous ablation (n   =   16) were identified from the 1,523 @entity1 with @entity409 metastases evaluated between January1993 and January 2013. RESULTS: Median @entity3012 was 25.9 months. Median @entity3012 was not different after ablation (18 months) and resection (26 months; P   >   0.2). @entity1 in the ablation group more often presented with @entity6687 ( @entity6687 ) (P   =   0.008) and received more frequently systemic therapy before ablation (P   =   0.005). @entity1 without @entity6687 tended to have longer @entity3012 (26.5 vs. 12 months; P   =   0.076) and PFS (13 vs. 5 months; P   =   0.11) in the whole cohort. @entity6687 was significantly associated with a worse @entity3012 in the resection group (P   =   0.034). CONCLUSION: Liver resection is associated to prolonged survival over 24 months and should be considered only in selected @entity1 with metastatic disease confined to the liver. In @entity1 not candidate for surgery, @entity5 ablation can be considered. J. Surg. Oncol. 2015 111:962-968.    2015 Wiley Periodicals, Inc.

title: Liver resection and ablation for XXXX : A single center experience.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['melanoma liver']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity6687 :: ('MESH:D001651', 'Disease') :: ['EHD', 'extrahepatic disease']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['metastatic melanoma']

answer: @entity320 :: (MESH:D008545,Disease) :: ['metastatic melanoma']


abstract: OBJECTIVES: A @entity3814 ( @entity3814 ) is characterized by back @entity158 and @entity174 of a vertebral body on spinal radiography. VCFs of the thoraco lumbar spine are common in the elderly. In general, appropriate analgesics should be prescribed to reduce @entity158 and, thus, promote early mobilization. The ideal treatment approach for VCFs has not been determined. In Korea, acupuncture and herbal medication have been used to treat VCFs for many years. There is empirical evidence that acupuncture might benefit @entity1 with a @entity3814 . However, no randomized, controlled, clinical trials evaluating the efficacy and the safety of acupuncture for treating a @entity3814 have been published. Therefore, we designed a randomized, controlled, pilot, clinical trial to obtain information for the design of a further full scale trial. METHODS: A five week protocol for a randomized, controlled, pilot, clinical trial is presented. Fourteen @entity1 will be recruited and randomly allocated to two groups: a control group receiving interlaminar epidural steroid injections once a week for three weeks, and an experimental group receiving interlaminar epidural @entity134 injections plus acupuncture treatment (three acupuncture sessions per week for three weeks, nine sessions in total). The primary outcomes will be the @entity158 intensity (visual analogue scale and PainVision(TM) system). The secondary outcome measurements will be the answers on the short form McGill @entity158 questionnaire and the @entity717 index. Assessments will be made at baseline and at one, three, and five weeks. The last assessment (week five) will take place two weeks after treatment cessation. This study will provide both an indication of feasibility and a clinical foundation for a future large scale trial. The outcomes will provide additional resources for incorporating acupuncture into existing treatments, such as nonsteroidal anti-inflammatory medications, narcotics and @entity3574 . This article describes the protocol.

title: Acupuncture in XXXX with a @entity3814 : a protocol for a randomized, controlled, pilot clinical trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fracture']

entities_list: @entity3574 :: ('OMIM:277300', 'Disease') :: ['vertebral augmentation']

entities_list: @entity3814 :: ('MESH:D050815', 'Disease') :: ['VCF', 'vertebral compression fracture']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['oswestry disability']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: PURPOSE: Childbearing delay contributes to the increase of subfertile couples that require assisted reproductive technology (ART). Subfertility relates with @entity249 ( @entity249 ). In vitro aging (IvA) (due to extended culture) may also impair oocyte competence. Aims of this study were to evaluate and compare the oocyte ultrastructure after @entity249 and IvA. METHODS: Cumulus-oocyte complexes (COCs) (n   =   68), with metaphase II oocyte and expanded cumulus, from consenting @entity1 (<35  years old and >= 35  years old, n   =   36), were selected by phase contrast microscopy and fixed at pick up, or after 24  h culture. COCs (n   =   44) were studied by light and qualitative/morphometric transmission electron microscopy. Two-way ANOVA, with age and culture as grouping factors, was applied for statistical analysis (p   <   0.05). Metaphase II cumulus-free oocytes (n   =   24) were selected for confocal microscopy observations. RESULTS: Significant decrease of mitochondria-smooth endoplasmic reticulum aggregates, increase of mitochondria-vesicle complexes size and amount, decrease of cortical granules and microvilli, and alterations of the spindle structure characterized both @entity249 and IvA oocytes. These changes were significantly more evident in the @entity249 oocytes submitted to IvA. @entity249 oocytes also showed changes of the zona pellucida and occurrence of vacuoles after culture. Cumuli appeared re-compacted after culture, irrespective of the age of the @entity1 . CONCLUSIONS: These data demonstrated that aging is related to decay of oocyte ultrastructural quality, and that oocytes from elder @entity1 are more sensitive to prolonged culture (IvA) than the oocytes from younger @entity1 . These morphological results should be considered when applying ART in aged @entity1 , rescue ICSI, or artificial oocyte activation.

title: Ultrastructural markers of quality are impaired in XXXX metaphase II aged oocytes: a comparison between reproductive and in vitro aging.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'women']

entities_list: @entity249 :: ('MESH:D007246', 'Disease') :: ['reproductive aging', 'RA']

answer: @entity1 :: (9606,Species) :: ['human']